Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

NCT03754140 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Unable to identify eligible patients within planned timeframe

Conditions

Melanoma
In-Transit Metastasis of Cutaneous Melanoma

Interventions

DRUG: Polidocanol Injection

Sponsor

Melanoma Institute Australia